Autolus Therapeutics Q2 EPS $(0.26) Misses $(0.22) Estimate
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics reported Q2 losses of $(0.26) per share, missing the analyst consensus estimate of $(0.22) by 18.18%. However, this is a 43.48% improvement over the same period last year.
August 04, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Autolus Therapeutics' Q2 earnings per share missed estimates, which could negatively impact the stock price in the short term.
Autolus Therapeutics reported a larger loss than expected for Q2, which could lead to a decrease in investor confidence and a potential drop in the stock price. However, the year-over-year improvement might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100